TG Therapeutics, Inc. (MHA) Announces Presentation of Phase 1 Data for Single-Agent Ublituximab (TG-1101) at the American Society of Clinical Oncology Meeting on June 2, 2013
5/16/2013 10:25:11 AM
More...
|
TG Therapeutics, Inc. (MHA) Announces First Quarter 2013 Financial Results and Business Update
5/14/2013 9:41:17 AM
More...
|
TG Therapeutics, Inc. (MHA) to Host Conference Call on First Quarter 2013 Financial Results and Business Update
5/10/2013 9:21:41 AM
More...
|
TG Therapeutics, Inc. (MHA) to Present at the 12th Annual Needham Healthcare Conference
4/30/2013 2:29:44 PM
More...
|
TG Therapeutics, Inc. (MHA) to Present at the 25th Annual ROTH Conference
3/18/2013 12:43:00 PM
More...
|
TG Therapeutics, Inc. (MHA) Initiates First-In-Human, Phase I Clinical Trial for Its Novel, Highly Specific PI3K-Delta Inhibitor, TGR-1202, in Patients With Hematologic Malignancies
1/8/2013 9:05:40 AM
More...
|
TG Therapeutics, Inc. (MHA) to Present at the 31st Annual J.P. Morgan Healthcare Conference
1/7/2013 9:54:12 AM
More...
|
TG Therapeutics, Inc. (MHA) Announces FDA Clearance to Commence Clinical Trials of Its Novel, PI3K-Delta Specific Inhibitor, TGR-1202, Under Its Recently Filed U.S. Investigational New Drug (IND) Application
1/3/2013 8:54:13 AM
More...
|
TG Therapeutics, Inc. (MHA) to Present at the Oppenheimer 23rd Annual Healthcare Conference
12/11/2012 9:39:54 AM
More...
|
TG Therapeutics, Inc. (MHA) Announces Poster Presentation Highlights for Ublituximab (TG-1101) and TGR-1202 From the 54th American Society of Hematology Meeting
12/10/2012 9:17:47 AM
More...
|
|